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a b s t r a c t
Coronary artery calcium (CAC) scan can be obtained using chest computed tomography,
with no use of contrast agents, and with a relatively low radiation exposure. The
mere absence of calcium is associated with a good prognosis in asymptomatic subjects
and in patients at low to medium risk of coronary artery disease. CAC can be quantiﬁed
in different ways, with higher scores being associated with a higher cardiovascular
risk. CAC carries both diagnostic and prognostic information over and above that
determined by classical risk factors. This paper presents the overview of the current
use of CAC scanning, its advantages and limitations, as well as potential future applica-
tions.
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Coronary artery calcium (CAC) deposits are almost entirely due
to atherosclerosis. It is, therefore, logical to expect that CAC
measurement may be a useful tool in excluding or conﬁrming
the presence of coronary artery disease (CAD) in subjects with
or without symptoms, but with no proven cardiovascular
disease (CVD).
CAC can be reliably assessed by means of computed
tomography (CT).
By the widely accepted deﬁnition, coronary calcium is
present when the threshold of 130 Hounsfeld units is exceeded
in at least 3 adjacent pixels [1].
Although multiple quantiﬁcation criteria can be applied,
the Agatston score, reﬂected in Agatston units (AU), and
determined by the product of the calciﬁed plaque area and
maximal calcium lesion density is most commonly used [2].
The lack of coronary calcium deposits does not exclude the
presence of obstructive changes in the coronary tree,
especially in patients aged <45 years. For example, in one
study including a group of 166 subjects with intermediate CAD
probability and CAC score (CACS) = 0 AU, a non-signiﬁcant
stenosis was present in 10%, and a signiﬁcant one in 2% of
patients [3]. In another study [4] no coronary lesions were
found in asymptomatic subjects, while 0.8% of those with
symptoms had soft obstructive changes. When it comes to
high-risk groups, like patients with symptoms suggestive of
ischemia who have clinical indications to invasive coronary
angiography, the prevalence of obstructive stenoses in those
with CACS = 0 may be as high as 19% [5].
In the MESA study, a positive CAC was a better predictor of
incident coronary events than carotid plaque presence and
increased carotid intima-media thickness [6].
In general, patients with no detectable CAC are at very low
risk of CV events. The presence of CAC increases the risk in an
incremental mode. In long-term, the relative risk of death or
MI is about threefold higher in patients with CACS 1–10 as
compared to those with negative CAC. A similar difference is
seen between individuals with CACS > 100 and those with
CACS values between 1 and 99 (RR 3.20; 95% CI 1.17–8.71) [7].
Traditionally, people with positive CAC, with the score
values 1–100, 100–400 and >400 AU, are considered to be at
low, intermediate and high risk of both ischemia and CV
events. CACS values >400 AU can be regarded as a CAD
equivalent, with a 10-year event rate of over 20%, even in
asymptomatic patients [1].
However, CACS interpretation should always take into
account the clinical context, including at least the symptoms
and age.
Measurement of CAC volume and density may have an
added value to the CACS measured in the Agatston units. In a
large cohort of patients in the MESA study, followed for themedian of 7.6 years, CAC volume showed an independent
positive association with CAD events, while CAC density was
associated with an independent inverse association at any
level of CAC volume [8]. Therefore, CAC density should
probably be taken into consideration in risk evaluation.
The American appropriateness use criteria for CT scanning
[9] give a limited mention to the non-contrast coronary CT as a
stand-alone diagnostic method. CACS assessment is deemed
appropriate in patients with positive family history of
premature CAD, and in asymptomatic subjects with no known
CAD being in the intermediate risk group, as assessed by age,
sex and symptoms.
The ESC guidelines on the management of patients with
stable CAD [10] underscore that the amount of calcium
correlates with the extent of atherosclerotic changes, but
the correlation with the presence of hemodynamically
signiﬁcant stenosis is rather poor. In practice, this means
that high CACS is not always associated with a signiﬁcant
coronary stenosis, and – on the other hand – the CACS = 0
cannot exclude CAD, especially in young patients presenting
with an acute coronary syndrome.
A comprehensive overview of the pathogenesis and
prognostic implications of coronary artery calciﬁcation can
be found in the paper by Madhavan et al. [11].
CAC in asymptomatic subjects
In a systematic review including more than 85,000 asymp-
tomatic subjects with CAC score = 0, only 0.56% experienced a
cardiovascular event during a mean follow-up of 51 months
[12]. Therefore, the absence of CAC was associated with a very
low risk of cardiovascular events (0.13% per year. The absence
of CAC had a 93–99% negative predictive value for detection of
signiﬁcant coronary lesions on invasive angiography.
Even low but positive CACS seem to be associated with an
increased risk as compared to those with no CAC in
asymptomatic subjects. In a subpopulation of patients from
the MESA study with CACS 0–10 AU, in the analysis adjusted
for age, gender, race and CAD risk factors, the subjects with
CACS 1–10 AU showed a threefold increase in risk of hard CAD
events (CAD death or non-fatal myocardial infarction) com-
pared to those with CACS = 0 [13].
Higher CACS value tend to bear an incremental risk of CAD
events.
Al Rifai et al. [14] followed-up a group of 4234 asymptomatic
subjects with CAC score ≥400 AU. Their mean age was 64 years,
males constituted 65% of the group, and the median CAC score
was 809. In multivariable analysis age, diabetes, smoking,
increasing CAC score and dyslipidemia were associated with 1-
year all-cause mortality (HR for CAC 1.33; 95% CI 1.11–1.56).
Diabetes and smoking showed the strongest association
(respective HR 2.62 and 2.42), suggesting that in the presence
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most important triggers of acute coronary events. Moreover, in
the subgroup of 781 individuals in whom hypertension was the
only risk factor, a positive CAC, irrespective of the numerical
value, was associated with an almost ﬁvefold increase in the
risk of death (HR 4.68 [95% CI: 2.22–9.87]) as compared to those
with no CAC.
In a recent subanalysis of the MESA study [15] CAC values
proved to be additive to the information on hyperlipidemia.
Subjects with CACS = 0 had cardiovascular event rates of 2.7–
5.9 per 1000 person-years, while in those with CACS ≥ 100 the
event rates were 22.7–29.5 per 1000 person-years, irrespective
of the presence and severity of lipid abnormalities.
CAC proved to be a useful predictor of CV events in
clinically healthy subjects with a positive family history of
premature coronary heart disease [16]. Relative to CACS = 0,
adjusted ratios for hard cardiovascular events were signiﬁ-
cantly increased in those with CACS values of 100–399 and
≥400 (HR 2.45; 95% CI 1.31–4.58, and 2.80; 95% CI 1.44–5.43,
respectively). In subjects with CACS 1–99, a similar, non-
signiﬁcant trend was observed. Again, in this study, CAC
appeared to be a robust marker of absolute and relative risk of
CV events.
Diabetes mellitus and some inﬂammatory disorders, such
as, e.g. ankylosing spondylitis and systemic lupus, can acceler-
ate coronary atherosclerosis. In this setting, early detection of
CAC is of special importance, since it may trigger introduction of
preventative measures at an early stage of CAD.
CAC in symptomatic subjects
The data on the value of CAC assessment in symptomatic
patients are scarce.
In a large systematic review, symptomatic subjects with
CACS = 0 had a low probability of an event (1.8% during a 42-
month follow-up, or 0.51% per year) [12].
Sosnowski et al. [17] examined a group of 362 consecutive
symptomatic subjects aged 45 years and less, and correlated
the presence of CAC with the risk factors, such as gender, body
mass index (BMI), smoking, blood pressure, lipids concentra-
tion, diabetes, physical activity and positive family history.
Almost 18% of all subjects had a positive CAC value. Apart from
male gender and the presence of diabetes, traditional risk
factors were unable to identify patients with premature
coronary atherosclerosis. Presence of at least 4 risk factors
was associated with more frequent positive CAC (26% vs 16%;
p < 0.05). CAC measurement can be justiﬁed in young
symptomatic people with a large number of risk factors, and
especially in males with diabetes.
In the setting of an acute coronary syndrome, the absence
of CAC, combined with undetectable high-sensitivity troponin
levels, may be useful in identifying patients who do not need
further evaluation [18].
It has been suggested that high CAC values are associated
with higher complication rates in patients undergoing
percutaneous coronary interventions [11]. Heavy calciﬁcations
are also linked to a worse coronary artery bypass surgery
outcome, due to incomplete revascularization and higher
likelihood of vein graft calciﬁcation [11].It needs to be emphasized, however, that there are no data
that CACS measurement would have any additional value over
and above the data provided by invasive coronary arteriogra-
phy.
Changes of CAC score over time
Among 3112 subjects with CACS = 0 at baseline, with mean age
of 58 years (64% female) included in the MESA study, 1125 (36%)
developed a positive CAC score at the follow-up ranging from 2
to 10 years. New CAC was generally present in one artery only,
and the score was low (median 7.1). Less than 5% of patients
had the CAC score >100 at the repeated scan. Mean time to
new calcium detection was 6.1 years [19]. These ﬁndings
suggest that using repeated CAC assessment, coronary
atherosclerosis can be detected in an early stage, when
aggressive preventive strategies may decrease the life-time
risk of CV events.
Based on the data from Heinz Nixdorf Recall Study, Erbel
et al. [20] suggest that progression of coronary calciﬁcation is
inevitable and predictable. They found that CACS tends to
exponentially increase with age, and the increase is, to some
extent, also related to blood pressure, lipid-lowering medica-
tion, diabetes and smoking. The classical CV risk factors,
however, had a limited inﬂuence on the CACS changes. In an
accompanying editorial Budoff makes the point that formation
of coronary calcium deposits may show different dynamics, and
that the individual progression rate may be a strong predictor of
cardiovascular events [21]. This view is corroborated by the data
from the MESA study, showing that in patients in whom the
increase in CACS exceeded 300 AU, the likelihood of incident
hard coronary events over 7.6-year follow-up was over 6 times
higher than in those with no progression [22].
Recommended intervals between the baseline and follow-
up CAC measurements may vary, depending on the clinical
setting. It is, however, believed, that asymptomatic subjects
with the initial CACS = 0 AU do not need a repeat study for at
least 4 years [1].
The effect of treatment on CAC
The effect of treatment on CAC has not been adequately
studied. There are no convincing data that any treatment is
associated with the decrease in CACS. Although statins are
known to lower clinical events, their use may be associated
with an increase rather than decrease of CACS. In a post hoc
patient-level analysis of 8 randomized trials, Puri et al. [23]
found that statins promote coronary atheroma calciﬁcation,
which may underlie plaque stabilization and, at least partially,
explain their clinical beneﬁt.
Should CAC assessment be supplemented with CT
angiography?
CAC evaluation can be considered as a stand-alone examina-
tion or in conjunction with CT coronary angiography. The
knowledge of coronary anatomy is essential in a number of
Table 2 – Current and potential indications for the CAC
evaluation.
Current indications [7]
Initial risk assessment in:
- symptomatic subjects with no known CAD, being in the
intermediate risk group
- patients with positive family history of premature CAD
Potential indications
- Longitudinal screening for CAC progression
- Establishing indications for preventive treatment
- Screening for CAC in symptomatic subjects with a large
number of risk factors
- Exclusion of an acute coronary syndrome (in conjunction
with troponin measurement)
- Exclusion of ischemic etiology in patients with heart failure
- Initial screening for CAC at the population level [29]a
a According to Naghavi et al. [29], women aged 55–75 years and
men aged 45–75 years may be considered.
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clinically relevant diagnostic and prognostic information of
the top of CAC measurement in subjects with no apparent CAD
remains a matter of controversy.
In the FACTOR-64 trial [24], 900 patients with diabetes but
no apparent cardiovascular disease were randomized to CT
angiography or usual care. Standard or aggressive care were
chosen based on the CT angiography ﬁndings. The mean
follow-up was 4  1.7 years. No signiﬁcant difference in the
composite outcome including all-cause mortality, non-fatal MI
or unstable angina requiring hospitalization, was observed
between CT-angiography-driven treatment and the control
group (HR 0.8, 95% CI 0.49–1.32; p = 0.38). Therefore, this study
did not support the CT angiography screening in this
asymptomatic, but high-risk population.
On the contrary, in the CONFIRM registry [25] including 8627
symptomatic patients without known CAD, who underwent
both CAC assessment and CT angiography, the CT angiogra-
phy was shown to have an incremental discriminatory power
to identify patients at risk of death or MI.
A signiﬁcant progress has been made in limiting radiation
exposure during coronary CT. It is likely that even with
coronary CT angiography, radiation exposure may be lower
than 0.5 mSv [26]. If this becomes reality, the applicability
of both CAC measurement and CT angiography will likely
increase.
Advantages and limitations of CAC assessment
Beneﬁts and problems related to CAC evaluation, as well as the
current and potential future application of CAC scanning have
been excellently addressed by Hecht in his recent review paper
[1]. Table 1 lists the most important beneﬁts and limitations of
CAC scanning.
Potential use of CAC
The role of CAC scoring in the current guidelines appears to be
underplayed. The indications to assess the CAC with no
visualization of coronary arteries should be possibly extended
to include the indications listed in Table 2.
The value of CAC measurement must be considered in
the context of multimodality imaging. In a cohort of 988
asymptomatic or symptomatic low-risk patients without prior
CAD, followed-up for a median of 6.9 years, relative value ofTable 1 – Benefits and problems of coronary artery
calcium scanning (modified after Hecht [1]).
Beneﬁts
- Risk stratiﬁcation superior to risk factors
- High net reclassiﬁcation index
- Gatekeeper to functional testing
- Cost effectiveness
- Radiation exposure similar to mammography
Problems
- Absence of randomized trialsFramingham risk score, CACS, exercise tolerance test (ETT),
and stress myocardial perfusion SPECT results were compared
as predictors of cardiac events, deﬁned as a composite of
cardiac death, non-fatal MI and the need for coronary
revascularization [27]. The cardiac event rate was 1.6% per
year. In this study, CACS signiﬁcantly improved long-term risk
stratiﬁcation beyond the Framingham risk score. ETT and
SPECT results, which supports the use of CACS as a ﬁrst-line
test for the assessment of long-term risk is this patient group.
In patients with heart failure, it is important to differentiate
between those with the ischemic vs non-ischemic etiology.
CACS, in most instances accompanied with CT angiography,
can serve this purpose, avoiding the need of invasive coronary
artery anatomy assessment.
Radiation exposure of CAC scoring (<1 mSv) is comparable
to mammography, which is widely used as a screening method
to detect breast cancer [28]. In this context, CACS measure-
ment may become an acceptable method to assess the
likelihood of incident cardiovascular events at the population
level. The deﬁnition of the cohort qualifying for screening
remains to be established. SHAPE investigators propose to use
it in women aged 55–75 and in men aged 45–75 years [29].
It has been also postulated that CAC measurement may be
a useful tool to qualify patients at risk of CAD to the polypill
preventive treatment [30]. This may be also true for more
patient-tailored treatment with statins, ACE inhibitors or
antiplatelet drugs.
Conclusions
The presence of calcium conﬁrms coronary atherosclerosis
and is associated with increased incidence of coronary events.
The presence and extent of CAC tends to be a better predictor
of future coronary events than the classical risk factors.
However, the results of CAC scanning should be always
interpreted in the clinical context, taking into account
patient's age and the presence or absence of symptoms.
Clinical usefulness of CAC measurement is likely to
increase in the future, especially with the advent of new
techniques reducing radiation exposure.
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